Applied DNA Sciences, Inc. and Alphazyme LLC (Alphazyme) announced the successful conclusion of the companies' previously announced Linea? RNAP manufacturing scale-up agreement. The joint process development project resulted in an over 70% reduction in Linea RNAP manufacturing costs and the manufacture of a quantity of Linea RNAP sufficient to support Applied DNA's anticipated near-term demand for critical starting material for mRNA production.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4084 USD | -0.73% | -14.92% | -96.69% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.69% | 4.17M | |
-11.78% | 11.24B | |
-13.76% | 7.29B | |
+29.50% | 5.57B | |
-0.19% | 5.31B | |
-19.19% | 3.68B | |
+7.62% | 2.58B | |
-65.24% | 2.33B | |
-10.48% | 2.23B | |
+27.80% | 2.21B |
- Stock Market
- Equities
- APDN Stock
- News Applied DNA Sciences, Inc.
- Applied DNA Sciences, Inc. and Alphazyme LLC Conclude Linea (TM) RNAP Manufacturing Scale-Up Project, Deliver Substantial Improvement in Linea (TM) IVT Platform Economics